XNASSCLX
Market cap114mUSD
Jan 07, Last price
0.48USD
1D
-5.82%
1Q
-41.28%
IPO
-94.86%
Name
Scilex Holding Co
Chart & Performance
P/E
—
P/S
2.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
47m
+22.90%
Net income
-114m
L+389.35%
CFO
-21m
L-2.59%
Profile
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 46,743 22.90% | 38,034 21.45% | |||
Cost of revenue | 28,427 | 19,851 | |||
Unusual Expense (Income) | |||||
NOPBT | 18,316 | 18,183 | |||
NOPBT Margin | 39.18% | 47.81% | |||
Operating Taxes | 13 | 4 | |||
Tax Rate | 0.07% | 0.02% | |||
NOPAT | 18,303 | 18,179 | |||
Net income | (114,331) 389.35% | (23,364) -73.58% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (10,000) | 96 | |||
BB yield | 3.76% | -0.02% | |||
| Debt | |||||
Debt current | 109,947 | 745 | |||
Long-term debt | 22,271 | 2,075 | |||
Deferred revenue | |||||
Other long-term liabilities | 4,592 | 4,781 | |||
Net debt | 128,297 | 636 | |||
| Cash flow | |||||
Cash from operating activities | (20,707) | (21,258) | |||
CAPEX | (30) | (2,067) | |||
Cash from investing activities | (330) | (2,067) | |||
Cash from financing activities | 23,582 | 21,171 | |||
FCF | 94,252 | (55,486) | |||
| Balance | |||||
Cash | 3,921 | 2,184 | |||
Long term investments | |||||
Excess cash | 1,584 | 282 | |||
Stockholders' equity | (490,229) | (375,897) | |||
Invested Capital | 451,105 | 418,327 | |||
ROIC | 4.21% | 4.90% | |||
ROCE | 42.85% | ||||
| EV | |||||
Common stock shares outstanding | 130,298 | 134,226 | |||
Price | 2.04 -48.87% | 3.99 | |||
Market cap | 265,808 -50.37% | 535,562 | |||
EV | 394,105 | 536,201 | |||
EBITDA | 22,462 | 22,144 | |||
EV/EBITDA | 17.55 | 24.21 | |||
Interest | 1,068 | 9,604 | |||
Interest/NOPBT | 5.83% | 52.82% | |||